全球类淀粉沉积症治疗市场规模、份额、成长分析（按最终用户、按治疗方法）- 产业预测，2024-2031 年

2022年全球类淀粉沉积症治疗市场规模估值为54.6亿美元，从2023年的58.7亿美元成长到2031年的58.7亿美元，预计在预测期内（2024-2031年）复合年增长率为7.6% 。

类淀粉沉积症是一种称为淀粉样蛋白的蛋白质在各个器官中异常积累，可导致器官功能障碍。儘管类淀粉沉积症是一种非常罕见的疾病，但由于认识和诊断率的提高，类淀粉沉积症治疗市场正在扩大。类淀粉沉积症的常见治疗方法包括化疗、干细胞移植以及小分子抑制剂和单株抗体等标靶药物。全球医学研发支出的快速成长也推动了类淀粉沉积症药物供应商的前景。类淀粉沉积症治疗的未来市场成长也可能受到对改善患者治疗结果、增加医疗保健支出、人口老化和医疗领域技术进步的日益关注的推动。由于全球对早期发现该疾病的需求不断增长，预计在预测期内对类淀粉沉积症治疗的需求将会增加。

目录

执行摘要

• 市场概况
• 命运之轮

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场危机与限制

母市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

主要市场考察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 创新矩阵
• 研发线产品分析
• 总体经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管环境
• 波特的分析
• 对未来中断的特殊考虑

全球类淀粉沉积症治疗市场：依最终用户分类

• 市场概况
• 医院
• 诊所
• 研究机构

类淀粉沉积症治疗的全球市场：依治疗分类

• 市场概况
• 化疗
• 干细胞移植
• 症状管理
• 新的治疗方法

全球类淀粉沉积症治疗市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 关键成功策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Alnylam Pharmaceuticals, Inc.（USA）
• Ionis Pharmaceuticals, Inc.（USA）
• Eidos Therapeutics, Inc.（USA）
• Prothena Corporation plc（Ireland）
• Akcea Therapeutics, Inc.（USA）
• Janssen Pharmaceuticals, Inc.（USA）
• GlaxoSmithKline plc（UK）
• Novartis International AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Sanofi SA（France）
• Ionis Pharmaceuticals, Inc.（USA）
• Oncopeptides AB（Sweden）
• Alexion Pharmaceuticals, Inc.（USA）
• Celgene Corporation（USA）[Acquired by Bristol-Myers Squibb]
• Amgen Inc.（USA）
• Caelum Biosciences（USA）
• Spectrum Pharmaceuticals, Inc.（USA）
• EUSA Pharma（UK）

Global Amyloidosis Treatment Market size was valued at USD 5.46 billion in 2022 and is poised to grow from USD 5.87 billion in 2023 to USD 10.56 billion by 2031, at a CAGR of 7.6% during the forecast period (2024-2031).

Amyloidosis is the abnormal build-up of proteins called amyloids in different organs that may cause organ malfunction. Despite being an extremely uncommon ailment, the market for amyloidosis treatments is growing as a result of rising awareness and diagnostic rates. Popular treatments for amyloidosis include chemotherapy, stem cell transplantation, and targeted medicines such small molecule inhibitors and monoclonal antibodies. Future prospects for suppliers of amyloidosis treatments are also being generated by the global upsurge in spending in medical R&D. Future market growth for amyloidosis therapy might also be aided by increased attention on improving patient outcomes, growing healthcare spending, an aging population, and technological improvements in the medical field. The need for amyloidosis treatment is expected to increase over the course of the projected period due to a growing global need for early detection of the disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Treatment Market Segmental Analysis

The global amyloidosis treatment market can be segmented based on treatment type, end-user, and region. Based on treatment type, the market includes chemotherapy, stem cell transplant, symptomatic management, and novel therapies such as monoclonal antibodies and RNA-targeted therapies. End-users encompass hospitals, clinics, and research institutions. Geographically, the market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Drivers of the Global Amyloidosis Treatment Market

Growing Prevalence of Amyloidosis: The need for amyloidosis therapy has grown due to an increase in the frequency of ATTR and AL amyloidosis worldwide. The burgeoning market for amyloidosis treatments is also being fueled by the expanding accessibility of sophisticated diagnostic techniques and rising public awareness of the disease.

Restraints in the Global Amyloidosis Treatment Market

Expensive therapy: Receiving therapy for amyloidosis can be expensive for patients, particularly if they want to use targeted medicines and other cutting-edge approaches. Long-term market growth for amyloidosis treatments is hampered by this increased cost burden.

Market Trends of the Global Amyloidosis Treatment Market

Developments in Targeted therapeutics: Research and development have made significant strides in the investigation and development of targeted therapeutics for amyloidosis. Small compounds and monoclonal antibodies were being extensively researched as possible therapies to prevent the disease's hallmark, the development or buildup of amyloid proteins. Several clinical trials were being conducted to assess the effectiveness and safety of these novel treatments.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Amyloidosis Treatment Market by End-user

• Market Overview
• Hospitals
• Clinics
• and Research Institutions

Global Amyloidosis Treatment Market by Treatment

• Market Overview
• Chemotherapy
• Stem Cell Transplant
• Symptomatic Management
• and Novel Therapies

Global Amyloidosis Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncopeptides AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA) [Acquired by Bristol-Myers Squibb]
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caelum Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EUSA Pharma (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments